Letroheal

Product Overview

Letroheal is a pharmaceutical preparation containing Letrozole as its active component. Classified as an aromatase inhibitor, this medication is primarily employed in managing hormone receptor-positive breast cancer. The therapeutic action involves blocking the aromatase enzyme that facilitates androgen-to-estrogen conversion in peripheral tissues. Through estrogen suppression, Letroheal effectively impedes the proliferation of hormone-dependent breast malignancies.

Therapeutic Applications

This medication is indicated for postmenopausal women diagnosed with estrogen receptor-positive breast carcinoma. Clinicians frequently prescribe it as adjuvant treatment post-surgical intervention to minimize recurrence potential. Additionally, Letroheal may be incorporated into multimodal treatment protocols alongside other oncological therapies for comprehensive disease management.

Administration Guidelines

The standard regimen involves oral administration once daily, with or without meals. Patients should ingest tablets whole with adequate water, avoiding crushing or chewing. Dosage parameters (typically 2.5 mg daily) are determined by the treating physician based on individual clinical response and tolerance. Strict adherence to prescribed dosing schedules is crucial for optimal therapeutic outcomes. Medical consultation is recommended for any administration-related queries.

Mechanism of Action

Letroheal exerts its pharmacological effect through selective, competitive inhibition of the aromatase enzyme system. This blockade prevents the peripheral conversion of adrenal androgens to estrogens, particularly significant in postmenopausal women. By creating an estrogen-depleted microenvironment, the medication starves hormone-sensitive neoplastic cells of their growth stimulus, thereby retarding tumor progression.

Dosage Protocol

The established therapeutic dose for breast cancer management is 2.5 mg administered once daily. Physicians may modify this regimen based on therapeutic response and adverse effect profile. Maintenance of consistent dosing intervals ensures stable plasma concentrations. Abrupt discontinuation without medical supervision is contraindicated due to potential disease exacerbation.

Therapeutic Advantages

• Demonstrated efficacy in reducing cancer recurrence rates
• Effective suppression of hormone-responsive tumor growth
• Simplified once-daily dosing schedule enhances compliance
• Compatibility with various combination therapy regimens
• Survival benefit demonstrated in postmenopausal breast cancer patients

Adverse Effects

Frequently reported reactions include vasomotor symptoms (hot flashes, night sweats), asthenia, cephalalgia, and musculoskeletal discomfort. These manifestations typically exhibit mild-to-moderate intensity and often attenuate with continued therapy. Persistent or severe symptoms warrant medical evaluation. Long-term use may predispose to decreased bone mineral density and increased fracture risk.

Precautions

Prior to initiation, disclose any history of metabolic bone disease, hepatic impairment, or renal dysfunction. The medication exhibits teratogenic potential – stringent contraception measures are mandatory during treatment. Comprehensive medication reconciliation is essential due to potential pharmacokinetic interactions with concomitant therapies, including herbal preparations.

Storage Conditions

Maintain tablets in original packaging at controlled room temperature (15-30°C), protected from humidity and direct sunlight. Ensure secure storage away from pediatric access. Discard any compromised or discolored tablets. Follow local regulations for proper disposal of unused medication.

Disclaimer:

This content is intended for educational purposes only, representing carefully vetted medical information. It does not substitute professional medical advice, diagnosis, or treatment. The complete safety profile, including potential drug interactions and contraindications, may not be fully detailed herein. Always consult qualified healthcare providers for personalized medical guidance. This information aims to complement, not replace, the essential physician-patient relationship.